Glaxo Group Limited

Philip Blatcher

David E Bays

Malcolm Clive Carter

Roger Hayes

Linda Carey

Roy Hornby

Martin Richard Owen

John W Clitherow

John Bradshaw

Barry J Price

Michael Martin-Smith

Richard Peter Charles Cousins

John W Mackinnon

Derek Norman Evans

A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.

Purine derivative

A process for the preparation of the compound of formula (I) ##STR1## or a salt thereof which comprises reducing the compound of formula (II) ##STR2## or a salt thereof. The novel intermediate of formula (II) and processes for preparing it are also described.

Process for the preparation of

This invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts and hydrates thereof, in which R.sub.1 represents a hydrogen atom or an alkyl, alkanoyl, aroyl or trifluoroalkyl group;

Heterocyclic derivatives

The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, and hydrates thereof. The substituents are defined in the specification. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

1,2,4-Triazole-3-amines, their pharmaceutical compositions and method of

The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined later. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

1,2,4-Triazole-3-amine and 1,2,4 triazole-3,5-diamine compounds and

Growing community of inventors

Stevenage, United Kingdom

Philip Blatcher